Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Some regulatory officials and lawmakers have raised concerns that manufacturer-linked DTP telehealth platforms could steer patients toward specific, high-cost branded products without adequate oversight, citing potential conflicts of interest, Anti-Kickback Statute risk, and past examples of elevated prescribing rates without independent clinical evaluation
The short-term gains are not worth the long-term damages
Additional caution is needed if there is a history of pancreatitis or problems with the pancreas
Doctors who treat obesity patients told Vox they wished they had a treatment option like semaglutide years ago, and patients described the drug as life-altering
From a regulatory standpoint, careful claim positioning is equally important
